CD116 Polyclonal Antibody BT-AP01342
Specifications
| 20ul / 50ul / 100ul |
Background:
Granulocyte-macrophage colony-stimulating factor receptor subunit alpha encoded by CSF2RA is the alpha subunit of the heterodimeric receptor for colony stimulating factor 2, a cytokine which controls the production, differentiation, and function of granulocytes and macrophages. The encoded protein is a member of the cytokine family of receptors. This gene is found in the pseudoautosomal region (PAR) of the X and Y chromosomes. Multiple transcript variants encoding different isoforms have been found for this gene, with some of the isoforms being membrane-bound and others being soluble.
Classification:
Primary antibody
Alternative names:
CSF2RA; CSF2R; CSF2RY; Granulocyte-macrophage colony-stimulating factor receptor subunit alpha; GM-CSF-R-alpha; GMCSFR-alpha; GMR-alpha; CDw116; CD antigen CD116
Species reactivity:
Human
Host:
Rabbit
Isotype:
IgG
Immunogen:
Synthesized peptide derived from the Internal region of human CD116.
Concentration:
1 mg/ml
Molecular weight:
46207
Applications:
WB, ELISA
Storage:
-20°C for one year
More info:
Email: info@sobekbio.com
Orders:
Email: orders@sobekbio.com
Fine Biotech is an ISO9001:2008 Certified Company,offers a full line of quality research kits,which include ELISA Kits,related ELISA assistant reagents and more high quality antibodies, recombinant proteins. Fine Biotech technical support are delicated to providing with professional and friendly assistance for our customers. Strict and multiple quality control ensure that our products continue to successfully supply for the international market. Moreover, we strive to continuously improve the customer experience through comprehensive technical support. High quality,rapid turnaround and personal support for all FineTest services are guaranteed. Should you have any problems,or any ideas on ways that we can improve our service,please feel free to call upon us.Thank you for your interest in FineTest products and we look forward to supplying you in the near future.